Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
Allergan Aesthetics (NYSE: ABBV), through its SkinMedica brand, announced an expanded commitment to regenerative science on July 14, 2026. The company launched the SkinMedica Regenerative Science Advisory Board, bringing together physicians, clinicians, and skin health experts to foster scientific dialogue, share clinical best practices, and connect breakthrough research with everyday patient care.
According to Allergan Aesthetics, SkinMedica also expanded its Irvine, California R&D lab to more than double its previous footprint, adding advanced pre-clinical research capabilities, sophisticated imaging, and AI- and machine learning–enabled discovery. In parallel, SkinMedica introduced its first in-practice flagship retail experiences at select U.S. medical aesthetics practices, including locations in Rapid City, South Dakota, and Scottsdale, Arizona, with more sites planned in 2026.
AbbVie (NYSE: ABBV) received European Commission marketing authorization for TEPKINLY (epcoritamab) + lenalidomide + rituximab (R2) to treat adult relapsed or refractory follicular lymphoma in the second-line setting. This fixed‑duration, chemotherapy‑free, bispecific-based regimen is the first of its kind approved in Europe.
In Phase 3 EPCORE FL-1, TEPKINLY + R2 reduced risk of progression or death by 79% (HR 0.21) versus R2, achieved 96% overall response and 74% complete response, versus 81% and 43% for R2. Serious adverse reactions occurred in 44% of patients, including cytokine release syndrome and infections.
AbbVie (NYSE: ABBV) reported positive topline Phase 3 EPCORE DLBCL-4 results for epcoritamab plus lenalidomide in adults with relapsed or refractory diffuse large B-cell lymphoma. The trial met its primary endpoint, showing statistically significant, clinically meaningful improvement in progression-free survival versus R-GemOx, with up to 60% lower risk of progression or death. The chemotherapy-free combination’s safety profile was consistent with the known profiles of epcoritamab and lenalidomide. AbbVie and Genmab plan to discuss next steps with global regulators and submit full data to a future medical meeting.
AbbVie (NYSE: ABBV) announced a positive CHMP opinion recommending approval of upadacitinib (RINVOQ) 15 mg and 30 mg once daily for adults and adolescents with severe alopecia areata in the EU. The opinion is based on Phase 3 UP-AA data showing SALT ≤ 20 and complete scalp regrowth (SALT = 0) at week 24, with a safety profile generally consistent with approved indications. A final European Commission decision is expected in the coming months.
AbbVie (NYSE: ABBV) received a positive CHMP opinion recommending approval of upadacitinib (RINVOQ 15 mg, once daily) for adults and adolescents with non-segmental vitiligo in the EU. If approved, it is expected to become the first systemic treatment for this chronic autoimmune skin disease.
The opinion is based on Phase 3 Viti-Up studies, where upadacitinib met co-primary endpoints (T-VASI 50, F-VASI 75) at week 48, with a safety profile consistent with approved uses.
AbbVie (NYSE:ABBV) announced U.S. FDA approval of SKYRIZI (risankizumab-rzaa) for children six years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis.
The approval adds a 55 mg pre-filled syringe for patients under 40 kg and keeps 150 mg options for those 40 kg or more, making SKYRIZI the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six and older under 40 kg with plaque psoriasis or psoriatic arthritis. Pediatric safety data were consistent with the established adult plaque psoriasis profile, supported by Phase 3 OptIMMize trials and pharmacokinetic modeling. AbbVie also highlights co-pay and assistance programs to help eligible families access treatment.
AbbVie (NYSE: ABBV) will announce its second-quarter 2026 earnings on Friday, July 31, 2026, before the market opens. The company will host a live earnings conference call webcast at 8 a.m. Central time, accessible via its investor relations website, with an archived replay available later that day.
BOTOX Cosmetic (NYSE: ABBV), from Allergan Aesthetics, introduced the 2026 cohort of The Confidence Collective: Empowering Women Entrepreneurs, selecting 250 women for a multi-week skill-building, mentorship, and networking program.
Twenty participants will each receive a $20,000 grant to support their business goals, with recipients to be announced in fall 2026.
Allergan Aesthetics (NYSE: ABBV) received Health Canada approval for Boey® (trenibotulinumtoxinE) to temporarily improve moderate to severe glabellar (frown) lines in adults.
Boey is the first approved serotype E aesthetic neurotoxin, offering rapid onset with results from about eight hours and a short duration of roughly two to three weeks.
AbbVie (NYSE: ABBV) received European Commission approval for MAVIRET (glecaprevir/pibrentasvir) to treat acute hepatitis C virus (HCV) infection with compensated liver disease, with or without cirrhosis, in adults and children aged 3+ years.
MAVIRET is now the only treatment approved in the EU for both acute and chronic HCV infection. Approval is supported by a Phase 3 study of an eight-week regimen, which showed high efficacy and mainly mild to moderate adverse events such as fatigue, diarrhea, headache and asthenia.